Orion Oyj (LON:0M2N)

Market Cap	8.23B +36.5%
Revenue (ttm)	1.70B +22.9%
Net Income	462.26M +52.4%
EPS	3.28 +52.1%
Shares Out	n/a
PE Ratio	17.80
Forward PE	15.58
Dividend	1.49 (2.22%)
Ex-Dividend Date	Mar 25, 2026

Volume	210
Average Volume	249
Open	67.30
Previous Close	67.10
Day's Range	67.30 - 67.30
52-Week Range	51.80 - 75.00
Beta	0.27
RSI	41.81
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,132
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2N

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Financial numbers in EUR